CSPC Pharmaceutical and AstraZeneca have signed a joint venture contract to establish a new-generation production facility in Shijiazhuang, China. The collaboration focuses on the manufacturing and global supply of mutually agreed biologics drug substances, with capital contributions structured at a 51:49 equity ratio in favor of CSPC Pharmaceutical. The agreement remains subject to customary closing conditions, including regulatory approvals.
Operational Management and Infrastructure Alignment
Under the terms of the contract, CSPC Pharmaceutical and AstraZeneca will jointly manage facility construction alongside day-to-day operations. The operational model combines CSPC Pharmaceutical’s AI-driven Good Manufacturing Practice system, construction infrastructure, and operational capabilities with AstraZeneca’s expertise in global quality standards and supply chain management. As commercial demand scales and production capacity increases, the companies plan to explore incorporating additional products into the scope of the joint venture.
Strategic Expansion in the Global Value Chain
The initial business scope centers on biologics drug substances destined for international markets. The partners will establish a state-of-the-art biologics manufacturing hub to serve global supply chains. CSPC Pharmaceutical highlights that this strategic agreement marks a significant progression in its internationalization strategy, transitioning from exporting products and technologies to supplying comprehensive manufacturing systems. As multinational pharmaceutical companies optimize research and production footprints, high-quality manufacturing capabilities serve as a core competency across the innovative drug value chain.
Continuation of Strategic Partnership
This initiative represents the third major strategic deal between CSPC Pharmaceutical and AstraZeneca in as many years. In June 2025, the two companies entered a strategic research collaboration to discover and develop preclinical oral candidates across multiple chronic indications using CSPC Pharmaceutical’s AI-driven drug discovery platform. That agreement involved an upfront payment of $110 million to CSPC Pharmaceutical, with eligibility for up to $1.62 billion in development milestone payments and upwards of $3.6 billion in sales milestone payments.
More recently, in January 2026, the companies entered a collaboration to advance next-generation therapies for obesity and type 2 diabetes across eight programs. Under that agreement, AstraZeneca secured exclusive global rights outside China to CSPC Pharmaceutical’s once-monthly injectable weight management portfolio, including SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, and three preclinical assets. This advancement enhances overall biologics manufacturing capabilities to meet international regulatory standards. The new facility in Shijiazhuang will strengthen supply capabilities to support the expanding pipeline emerging from the alliance.
